Skip to main content

Pacylex to Meet with Investors at Bio CEO Conference (BCIC) in New York City, February 26-27, 2024

By: Newsfile

Edmonton, Alberta--(Newsfile Corp. - February 23, 2024) - Pacylex Pharmaceuticals, a biotechnology company dedicated to developing innovative therapies for cancer and autoimmune diseases, announced that CEO Michael Weickert will attend the upcoming BIO CEO & Investor Conference in NYC and will be meeting with investors regarding the company's Series B funding round. The company's lead candidate, zelenirstat, is a first-in-class, orally bioavailable small molecule myristoylation inhibitor, a new mechanism of action for cancer treatment. Zelenirstat is currently being studied in patients who have failed available treatments (refractory or relapsed; r/r). It is in Phase 2 for patients with r/r B-cell non-Hodgkin lymphoma (NHL) and is about to begin Phase 2a in various r/r solid tumors, especially colorectal cancer, and Phase 1/2 in r/r acute myeloid leukemia (AML). Pacylex recently presented Phase 1 results in gastrointestinal cancers at the ASCO-GI conference in San Francisco in January 2024, including a colorectal patient who had been on therapy for more than 340 days and counting with a reduction in tumor volume and blood cancer marker.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • If you are attending BIO CEO & Investors, we would like to talk to you about investing in Pacylex and zelenirstat, a first-in-class oral cancer drug in Phase 2.
  • Zelenirstat has a great safety profile and evidence of benefit in refractory patients with solid and liquid tumors. Activity in vitro is 10x ibrutinib, and zelenirstat is highly synergistic with venetoclax.
  • This capital-efficient company has gotten to Phase 2 on <$20m so this is an excellent opportunity to invest in a significantly derisked FIC oncology pioneer with extraordinary potential.

Cannot view this image? Visit:

Click image above to view full announcement.

About zelenirstat (PCLX-001)

Zelenirstat (formerly identified as PCLX-001) is a first-in-class, oral, small molecule N-myristoyltransferase (NMT) inhibitor being developed to treat patients with leukemia, lymphoma, and solid tumors. In animal models, zelenirstat selectively killed cancer cells in vitro and has been shown to regress hematologic malignancies and inhibit the growth of lung and breast cancer tumors. In AML models, zelenirstat killed leukemic stem enriched cell populations and allowed the regeneration and growth of normal bone marrow cells.

About zelenirstat Phase 1 and 2 studies 

Pacylex completed the dose escalation phase of a Phase 1 multiple ascending dose safety, tolerability, and pharmacokinetics study on zelenirstat in R/R lymphoma and solid tumor patients (NCT04836195). A recommended Phase 2 dose was determined. Zelenirstat demonstrated an acceptable safety and tolerability profile, pharmacokinetics consistent with once daily oral dosing, and early signs of potential efficacy.

Zelenirstat is currently being studied in a Phase 2a open-label study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of zelenirstat in patients with R/R B-cell non-Hodgkin Lymphoma (NHL). A separate Phase 2a cohort is planned in advanced solid malignancies who have progressed on all available standard therapies.

About Pacylex Pharmaceuticals
Pacylex is a clinical-stage pharmaceutical company headquartered in Edmonton, Alberta, Canada, targeting hematologic and solid cancers with orally bioavailable NMT inhibitors. Zelenirstat is the lead drug in a new class of NMT inhibitors, enabling Pacylex to exploit NMTs as new clinical targets for cancer treatment. Pacylex is conducting a multi-center Phase 1/2a study in Canada in patients with R/R NHL and advanced solid tumors. The IND for a Phase 1 multiple ascending dose study in acute myeloid leukemia (AML) has been cleared and the FDA has granted zelenirstat both Orphan Drug Designation and Fast Track Designation for AML. The US Department of Defense is supporting the initial clinical investigation of zelenirstat in patients with AML. The Cure Cancer Foundation supported initial clinical studies through its World's Longest Games. 

Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, such as statements relating to future events or the Company's future financial and operating performance, as well as the Company's business plans, growth initiatives, and objectives and prospects. Generally, forward-looking statements and forward-looking information may be identified by the use of forward-looking terminology, including the words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "goal," "expect," "strategy," "future," "likely," "proposed," "scheduled," "forecast," "budget," "could," "would," variations of such words of phrases and other similar expressions, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. However, the absence of these words does not mean that a statement is not forward looking. Forward-looking statements and forward-looking information are subject to numerous factors, risks and uncertainties that could cause actual results to differ materially, including, but not limited to, the Company's ability to successfully execute on its business plans and strategies, avoid delays in planned clinical trials, hire and retain key personnel, obtain appropriate or necessary governmental approvals to market potential products and obtain future funding for product development and working capital on commercially reasonable terms, changes in laws, and  general macroeconomic conditions, including economic slowdowns, recessionary risks, rising inflation and interest rates, and supply chain disruptions. Forward-looking statements and forward-looking information are based on the beliefs of management as well as assumptions made by and information currently available to management as of the date hereof, and none of the Company or its affiliates undertakes any obligation to update or issue revisions to any forward-looking statements or forward-looking information contained herein to reflect any future events or circumstances, except as required by law. The foregoing does not constitute an offer or solicitation to acquire any securities in the Company or any related or associated entity or affiliate. The information contained herein is not intended as legal, tax, financial or investment advice. Furthermore, the information contained herein may not be applicable to or suitable for an individual's specific circumstances or needs.


Michael Weickert Ph.D

Source: Pacylex

To view the source version of this press release, please visit

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.